Market Overview

Inside Sarepta's Beat And Raise Q2

Inside Sarepta's Beat And Raise Q2
Related SRPT
Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics
Benzinga's Top Upgrades, Downgrades For March 21, 2018

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares jumped up over 17 percent during Wednesday’s after-hours trading sessions, after the medical research and drug development company crushed earnings estimates.

A Closer Look At Q2 Earnings

  • Revenue: $35 million (consensus estimate was $22.3 million)
  • Adjusted Losses: $0.46 per share (was $1.19 per share last year)
  • Guidance: Raised to $125 million–$130 million (was $95 million)

After Nomura managing director Christopher Marai spoke to new CEO Doug Ingram following the earnings call, he also highlighted a positive view on Sarepta’s future similar to Ingram’s March 1 invitation theses. Marai maintains his Buy rating and set an $84 price target.

According to TipRanks, eight analysts are averaging a strong buy rating and a price target of $66 on Sarepta. Shares of Sarepta were trading at $40.20 during Thursday’s pre-market session, and at time of publication, shares were up 21.01 percent at $41.24.

To read the latest and exclusive financial news, visit the Benzinga Pro news wire.

Latest Ratings for SRPT

Mar 2018Morgan StanleyDowngradesOverweightEqual-Weight
Mar 2018JP MorganMaintainsOverweightOverweight
Mar 2018Credit SuisseMaintainsOutperformOutperform

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Earnings Long Ideas News Guidance Price Target Reiteration Best of Benzinga


Related Articles (SRPT)

View Comments and Join the Discussion!